Applied Filters
LSIPR 50 2018: Backing the innovators
Josh Makower, partner at venture capital investor New Enterprise Associates, explains to LSIPR the firm’s role in supporting medtech innovation, his sweet spot when it comes to projects, and how to balance what is medically relevant with commercial viability.
The future of precision medicine part 2: data is king
In the area of precision medicine, there are questions surrounding what data is needed, how it is used, what it should look like and what concerns there are for patients and society, as Daniel Lim of Kirkland & Ellis reports.
Will the EPO’s Enlarged Board hear the Broad’s CRISPR case?
As the Broad Institute faces a formidable task in defending its revoked CRISPR patent claims in a pending appeal at the EPO, European academics Jakob Wested, Timo Minssen, and Esther van Zimmeren are wondering whether some of the issues might be referred to the Enlarged Board of Appeal.
LSIPR 50 2018: Leading the transformation change
Scott Alban of AstraZeneca outlines the company’s recent transformation aimed at breaking down barriers and the uncharted territories that it is eager to explore.
LSIPR 50 2018: Helping to shape the healthcare landscape
A lack of blood donors and poor healthcare infrastructure inspired Temie Giwa-Tubosun to develop and deliver a life-saving app. LSIPR spoke to the founder of LifeBank.
LSIPR 50 2018: It’s not like selling cars
Balancing a company’s duty to shareholders with the public responsibility to provide lifesaving treatments is a constant challenge, as Issi Rozen, chief business officer at the Broad Institute of MIT and Harvard, tells LSIPR.
The future of precision medicine part 1: challenges and opportunities
The healthcare industry and governments around the world are turning to precision medicine as an opportunity and a potential saviour. Daniel Lim of Kirkland & Ellis discusses the issues around translating the promise of precision medicine into real world clinical practice.
Keeping trade fair
As Mexico prepares for a presidential election in 2018, pharma IP owners are hoping that the progress made in trade negotiations is not undone. Hector Chagoya of Becerril Coca & Becerril reports.
Post-grant proceedings: shaping the biotech landscape
It is certain that both inter partes and post-grant reviews will continue to shape the landscape for biologics patents and biosimilars, says Jennifer Fox of Brinks Gilson & Lione.
Can a computer invent a drug?
Artificial intelligence is being used increasingly in the pharma and biotech industries, and questions are being asked about the legal status of innovations created by the technology, as MaryAnne Armstrong of Birch, Stewart, Kolasch & Birch reports.
